Hypertension and QT interval prolongation associated with targeted systemic cancer therapies

Abstract

Objective

To summarize the proposed mechanisms behind hypertension and QT interval prolongation associated with use of targeted systemic cancer therapies and provide recommendations for monitoring or managing these toxicities.

Summary

The cardiotoxic effects of targeted systemic cancer therapies represents a new paradigm of cancer treatment associated cardiovascular adverse events. National guidelines regarding optimal monitoring and management strategies for hypertension and QT interval prolongation associated with use of these therapies are lacking. While the pathophysiological drivers of hypertension due to targeted systemic cancer therapies differ by class of targeted therapy, general management strategies do not. Routine blood pressure monitoring throughout the duration of therapy is recommended for all agents. Patients who experience hypertension often can be treated with the addition or modification of antihypertensive therapies. Uncontrolled hypertension despite optimal medical management may require dose modifications or discontinuation of the targeted systemic cancer therapy. Electrocardiogram monitoring is recommended for patients who receive targeted therapies that may prolong the QT interval. Minimizing or managing drug interactions with other QT prolonging medications is recommended in addition to ensuring adequate electrolyte supplementation. Dose modifications or discontinuation of the targeted systemic therapy may be necessary for patients who experience QT interval prolongation.

Conclusions

Appropriate cardiovascular monitoring and timely management of treatment-emergent toxicities can optimize therapy for patients receiving targeted systemic cancer therapies associated with a risk of drug-induced hypertension or QT interval prolongation.

Keywords

Hypertension prolonged QT interval cardio-oncology targeted systemic cancer therapy oncology pharmacy

Get full access to this article

View all access options for this article.

References

Manolis

Mikhailidis

, et al. Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – part 1. Expert Opin Drug Saf 2018; 17: 875–892.

Wickramasinghe

Nguyen

Watson

, et al. Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity. Future Oncol 2016; 12: 855–870.

O'Hare

Murphy

Mookadam

, et al. Cardio-oncology part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity. Expert Rev Cardiovasc Ther 2015; 13: 519–527.

Zamorano

Lancellotti

Rodriguez Munoz

, et al.; ESC Scientific Document Group. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J 2016; 37: 2768–2801.

Curigliano

Cardinale

Suter

, et al.; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 2012; 23(Suppl 7): vii155–vii166.

U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute. Common terminology criteria for adverse events (CTCAE), https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (2017, accessed 4 February 2020).

Aparicio-Gallego

Afonso-Afonso

Leon-Mateos

, et al. Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs 2011; 22: 1–8.

O'Hare

Sharma

Murphy

, et al. Cardio-oncology part I: chemotherapy and cardiovascular toxicity. Expert Rev Cardiovasc Ther 2015; 13: 511–518.

Zhu

Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. Clin Hypertens 2019; 25: 12.

10.

Alunbrig TM [package insert]. Cambridge, MA: ARIAD Pharmaceuticals Inc., 2018.

11.

Imbruvica(R) [package insert]. Horsham, PA: Pharmacyclics LLC, 2019.

12.

Zytiga(R) [package insert]. Horsham, PA: Janssen Biotech, Inc., 2019.

13.

Zejula(R) [package insert]. Waltham, MA: Tesaro, Inc., 2019.

14.

Aliqopa TM [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc., 2019.

15.

Inlyta(R) [package insert]. New York, NY: Pfizer Laboratories Div Pfizer Inc., 2019.

16.

Avastin(R) [package insert]. South San Francisco, CA: Genentech, Inc., 2019.

17.

Cabometyx(R) [package insert]. Alameda, CA: Exelixis, Inc., 2019.

18.

Cometriq(R) [package insert]. Alameda, CA: Exelixis, Inc., 2019.

19.

Lenvima(R) [package insert]. Woodcliff Lake, NJ: Eisai Inc., 2019.

20.

Votrient(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2019.

21.

Iclusig(R) [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc., 2018.

22.

Cyramza(R) [package insert]. Indianapolis, IN: Eli Lilly and Company, 2019.

23.

Stivarga(R) [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc., 2019.

24.

Nexavar(R) [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc., 2018.

25.

Sutent(R) [package insert]. New York, NY: Pfizer Laboratories Div Pfizer Inc., 2019.

26.

Caprelsa(R) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2016.

27.

Zaltrap(R) [package insert]. Bridgewater, NJ: Sanofi-Aventis, 2020.

28.

Armanini

Andrisani

Ambrosini

, et al. Role of adrenocorticotropic hormone in essential hypertension and primary aldosteronism. J Clin Hypertens (Greenwich) 2017; 19: 287–289.

29.

Ferrari

RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract 2013; 2013: 269–278.

30.

Eltantawy

Vallejos

Sebea

, et al. Copanlisib: an intravenous phosphatidylinositol 3-kinase (PI3K) inhibitor for the treatment of relapsed follicular lymphoma. Ann Pharmacother 2019; 53: 954–958.

31.

Mensah

Blaize

Bryan

LJ.

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. Oncol Targets Ther 2018; 11: 4817–4827.

32.

Doi

Fuse

Yoshino

, et al. A phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. Cancer Chemother Pharmacol 2017; 79: 89–98.

33.

Ison

Howie

Amiri-Kordestani

, et al. FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy. Clin Cancer Res 2018; 24: 4066–4071.

34.

Moore

Mirza

Matulonis

UA.

The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities. Gynecol Oncol 2018; 149: 214–220.

35.

Okamoto

Shibao

Gamboa

, et al. Synergistic effect of norepinephrine transporter blockade and alpha-2 antagonism on blood pressure in autonomic failure. Hypertension 2012; 59: 650–656.

36.

Zeng

Jose

PA.

Dopamine receptors: important antihypertensive counterbalance against hypertensive factors. Hypertension 2011; 57: 11–17.

37.

Caldeira

Alves

Costa

, et al. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One 2019; 14: e0211228.

38.

Manohar

Bansal

Wanchoo

, et al. Ibrutinib induced acute tubular injury: a case series and review of the literature. Am J Hematol 2019; 94: E223–E225.

39.

Dharmashankar

Widlansky

ME.

Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep 2010; 12: 448–455.

40.

Manolis

Mikhailidis

, et al. Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – part 2. Expert Opin Drug Saf 2018; 17: 893–915.

41.

James

Oparil

Carter

, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA 2014; 311: 507–520.

42.

Whelton

Carey

Aronow

, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension 2018; 71: e13–e115.

43.

Maitland

Bakris

Black

, et al.; Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.

44.

Rini

Cohen

, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–773.

45.

Sundar

Dickinson

PD.

Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. BMJ Case Rep 2012; 2012: 1–4.

46.

Cheson

O'Brien

Ewer

, et al. Optimal management of adverse events from copanlisib in the treatment of patients with non-Hodgkin lymphomas. Clin Lymphoma Myeloma Leuk 2019; 19: 135–141.

47.

Cardizem(R) [package insert]. Bridgewater, NJ: Bausch Health US, LLC, 2020.

48.

Verelan(R) [package insert]. Philadelphia, PA: Lannett Company, Inc., 2020.

49.

Sharom

FJ.

The P-glycoprotein multidrug transporter. Essays Biochem 2011; 50: 161–178.

50.

Coreg [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2017.

51.

Alexandre

Moslehi

Bersell

, et al. Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms. Pharmacol Ther 2018; 189: 89–103.

52.

Rabkin

Cheng

XB.

Nomenclature, categorization and usage of formulae to adjust QT interval for heart rate. World J Cardiol 2015; 7: 315–325.

53.

Muluneh

Richardson

Hicks

, et al. Trials and tribulations of corrected QT interval monitoring in oncology: rationale for a practice-changing standardized approach. JCO 2019; 37: 2719–2721.

54.

Food and Drug Administration: clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs – questions and Answers (R3). Guidance for Industry (2017, accessed 26 January 2020).

55.

Food and Drug Administration: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (2005, accessed 26 January 2020).

56.

Porta‐Sánchez

Gilbert

Spears

, et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc 2017; 6: e007724.

57.

Zykadia(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2019.

58.

Xalkori(R) [package insert]. New York, NY: Pfizer Laboratories Div Pfizer Inc., 2019.

59.

Braftovi(R) [package insert]. Boulder, CO: Array BioPharma Inc., 2019.

60.

Rozlytrek TM [package insert]. South San Francisco: Genentech Inc., 2019.

61.

Xospata(R) [package insert]. Northbrook IL: Astellas Pharma US, Inc., 2019.

62.

Daurismo TM [package insert]. New York, NY: Pfizer Laboratories Div Pfizer Inc., 2019.

63.

Tibsovo(R) [package insert]. Cambridge, MA: Agios Pharmaceuticals, Inc., 2019.

64.

Tykerb(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2019.

65.

Tasigna(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2019.

66.

Tagrisso(R) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2019.

67.

Kisqali(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2019.

68.

Zelboraf(R) [package insert]. South San Francisco, CA: Genentech, Inc., 2018.

69.

Umar

RM.

Drug-drug interactions between antiemetics used in cancer patients. J Oncological Sci 2018; 4: 142–146.

70.

Brygger

Herrstedt

; Academy of Geriatric Cancer Research (AgeCare). 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin Drug Saf 2014; 13: 1407–1422.

71.

FDA Drug Safety Communication: abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate) (accessed 15 April 2020).

72.

Ettinger

Berger

Barvour

, et al. Antiemesis (2020, accessed 15 April 2020).

73.

Doggrell

Hancox

JC.

Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf 2013; 12: 421–431.

74.

FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran) (accessed 15 April 2020).

75.

Sancuso (R) [package insert]. Bedminster, NJ: Kyowa Kirin, Inc., 2017.

76.

Aloxi(R) [packge insert]. Woodcliff Lake, NJ: Eisai Inc., 2015.

77.

Grande

Kreissl

Filetti

, et al. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther 2013; 30: 945–966.

78.

Baden

Swaminathan

Prevention and treatment of cancer-related infections. In: NCCN clinical practice guidelines in oncology. Plymouth Meeting, PA: National Comprehensive Cancer Network, 2017, p. INF-1 through p. MS-113.

79.

Cresemba [package insert]. Northbrook, IL: Astellas Pharma US Inc., 2019.